Xeris Pharmaceuticals: Q1 Earnings Insights

Shares of Xeris Pharmaceuticals XERS gained 11% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 16.82% year over year to ($0.89), which were in line with the estimate of ($0.89).

Revenue of $1,788,000 rose by 620.97% year over year, which beat the estimate of $1,430,000.

Guidance

Xeris Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Price Action

52-week high: $12.98

52-week low: $1.42

Price action over last quarter: Up 48.60%

Company Description

Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. Its pipeline products are Diazepam, Pramlintide-Insulin, Self-Administered Glucagon, and others.